We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion.
- Authors
Hernandez, Michelle; Sullivan, Ryan D.; McCune, Mariana E.; Reed, Guy L.; Gladysheva, Inna P.
- Abstract
Pathological sodium-water retention or edema/congestion is a primary cause of heart failure (HF) decompensation, clinical symptoms, hospitalization, reduced quality of life, and premature mortality. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) based therapies reduce hospitalization due to HF, improve functional status, quality, and duration of life in patients with HF with reduced ejection fraction (HFrEF) independently of their glycemic status. The pathophysiologic mechanisms and molecular pathways responsible for the benefits of SGLT-2i in HFrEF remain inconclusive, but SGLT-2i may help HFrEF by normalizing salt-water homeostasis to prevent clinical edema/congestion. In HFrEF, edema and congestion are related to compromised cardiac function. Edema and congestion are further aggravated by renal and pulmonary abnormalities. Treatment of HFrEF patients with SGLT-2i enhances natriuresis/diuresis, improves cardiac function, and reduces natriuretic peptide plasma levels. In this review, we summarize current clinical research studies related to outcomes of SGLT-2i treatment in HFrEF with a specific focus on their contribution to relieving or preventing edema and congestion, slowing HF progression, and decreasing the rate of rehospitalization and cardiovascular mortality.
- Subjects
HEART failure; VENTRICULAR ejection fraction; EDEMA; BRAIN natriuretic factor; EARLY death; MEDICAL research; PEPTIDES; ALDOSTERONE antagonists
- Publication
Diagnostics (2075-4418), 2022, Vol 12, Issue 4, p989
- ISSN
2075-4418
- Publication type
Article
- DOI
10.3390/diagnostics12040989